Dynavax Technologies Corporation is a biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company's development programs are focused on vaccines for hepatitis B, influenza, and COVID-19, as well as cancer immunotherapy. Dynavax's lead product candidate is HEPLISAV-B, a hepatitis B vaccine for adults. The Company's other products include SD-101, an investigational cancer immunotherapeutic that is in Phase 2 studies, and DV281, an investigational TLR9 agonist that is in Phase 1 studies. Dynavax is headquartered in Berkeley, California.